Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified for the September 28 decline. - The September 25 announcement covered preclinical Annamycin pancreatic-cancer findings presented at AACR. The company cautioned that preclinical results may not predict human outcomes, and Annamycin is not in clinical development for pancreatic cancer. - The Nasdaq is down 0.90% and the S&P 500 is down 0.40%. Broader weakness may add pressure but does not establish the cause of the stock’s move.